Johnson & Johnson gets FDA nod for new depression treatment
This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials
This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials
The FDA setback highlights ongoing tensions between patient needs, regulatory processes, and the use of real-world evidence in evaluating treatments for rare diseases
Collaboration aims to deliver rapid, lab-quality testing to communities worldwide – making precision health more accessible
The study demonstrated strong clinical outcomes, with 94.8 per cent of subjects remaining free from major target limb amputation at one year
Vitiligo, affecting over 90 per cent of patients in its non-segmental form, is characterized by symmetrical white patches on both sides of the body
Approval based on pivotal KOMET Phase III trial demonstrating significant tumour reduction in adults with NF1
Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions
This approval marks a significant milestone in women’s health, introducing Bayer’s first hormone-free treatment for menopause-related symptoms
The Fast Track Designation was supported by nonclinical data as well as clinical results from the ongoing Phase I/IIa trial evaluating the safety and tolerability
Subscribe To Our Newsletter & Stay Updated